amivantamab,lazertinib
janssen,yuhan corp
['biomarker', 'amivantamab', 'lazertinib', 'lcsm,(-blcsm)', 'chrysalis-2']
comparative met-ihc and ctdna ngs analysis in chrysalis-2 (post-osi amivantamab plus lazertinib) by . must-to-check predictive biomarker research to understand egfr-met bispecific antibody (orr 61%, mpfs 12.2m in met+). met-ihc (sp44) revisited! #asco23 #lcsm 
Medical Oncologist, National Cancer Center Hospital, Lung Cancer Study Group @JCOG_official, Educational Committee @JSMO_official, @JLCS_OFFICIAL, @IASLC